BiologicsRegulatoryTop Stories

Mg OSTEOINJECT from Bone Solutions Receives 510(k) Clearance for Expanded Indications

Colleyville, TX, July 13, 2022 /OrthoSpineNews/— Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today that it has received FDA 510(k) clearance for expanded indications for its Mg OSTEOINJECT. Mg OSTEOINJECT is the first drillable, adhesive, and injectable bone void filler in the U.S. to incorporate magnesium, a critical component for bone health and development.


The expanded indication includes use of the material as an adjunct to hardware fixation by supporting the bone fragments during the surgical procedure. Magnesium-based Mg OSTEOINJECT showed nearly 30% greater anchoring strength compared to traditional PMMA.1

Mg OSTEOINJECT also provides a minimally invasive treatment option for insufficiency and micro fractures via percutaneous skeletal fixation. The adhesive properties and unique resorption profile of Mg OSTEOINJECT provide stability, increasing cell proliferation and advancing mineralization that results in enhanced bone regeneration in a broad range of orthopedic applications.

Mg OSTEOINJECT is currently being distributed to facilities and surgical centers nationwide for immediate clinical use.


About Bone Solutions Inc.

Bone Solutions Inc. (‘BSI’) is a specialized medical device company dedicated to improving clinical outcomes through biologically safe, fully resorbable magnesium-based orthopedic implant solutions, with a focus on addressing complex procedures and cost reduction. The company is developing various new orthopedic technologies within its FDA-cleared magnesium-based platform.

1Bertone, AL; DeMaria, MG; Johnson, AL; Weisbrode, SE; Kowaleski, MP, Comparative Orthopaedic Research and Bone Laboratories, College of Veterinary Medicine, The Ohio State University, Columbus, OH, 52nd Annual Meeting of the Orthopaedic Research Society, Paper No: 0876 “Degradable Magnesium Based Cement Adheres Stainless Steel Screws Into Bone.”

“Mg OSTEOINJECT” is a registered trademark of Bone Solutions, Inc.

Media Contact: Paul Williams, MediaLine Communications, 310-569-0023

Company Contact: Drew Diaz, Bone Solutions Inc., 817-809-8850

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button